Comparative Pharmacology
Head-to-head clinical analysis: KOSELUGO versus MEKTOVI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KOSELUGO versus MEKTOVI.
KOSELUGO vs MEKTOVI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of MEK1 and MEK2, downstream kinases in the RAS/RAF/MEK/ERK signaling pathway. Inhibits cell proliferation and induces apoptosis in tumor cells with activating mutations in BRAF or RAS.
MEKTOVI (binimetinib) is a reversible, non-competitive inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2. It inhibits the MAPK/ERK pathway, which is activated in tumors with BRAF mutations.
600 mg orally twice daily on an empty stomach (at least 1 hour before or 2 hours after a meal).
45 mg orally twice daily, approximately 12 hours apart
None Documented
None Documented
Terminal elimination half-life is approximately 23-25 hours, supporting once-daily dosing with steady-state achieved within 5 days.
Terminal elimination half-life is approximately 3.7 days (range 2.5–6.3 days) in patients with advanced solid tumors. This long half-life supports once-daily dosing.
Primarily excreted via feces (94%) with minimal renal excretion (<1% unchanged in urine). Biliary excretion accounts for a minor pathway.
Primarily fecal (94% of total radioactivity) with minimal renal excretion (4% of total radioactivity). Unchanged drug accounts for approximately 27% of the dose in feces.
Category C
Category C
MEK Inhibitor
MEK Inhibitor